Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
30 August 2022 - 9:00PM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced that
Dr. Neal Walker, CEO of Aclaris, will virtually present a company
overview at the H.C. Wainwright 24th Annual Global Investment
Conference, which will be available on-demand beginning on Monday,
September 12, 2022 at 7:00 a.m. ET. Management will be available
September 12th throughout the day for virtual 1x1 meetings.
A webcast of the presentation may be accessed through the
“Events” page of the “Investors” section of Aclaris’ website,
www.aclaristx.com. The webcast will be archived for at least 30
days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates to address
the needs of patients with immuno-inflammatory diseases who lack
satisfactory treatment options. The company has a multi-stage
portfolio of drug candidates powered by a robust R&D engine
exploring protein kinase regulation. For additional information,
please visit www.aclaristx.com.
Aclaris Contact
investors@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2023 to Apr 2024